Eli Lilly
Mentioned in 54 analyzed podcast episodes across 10 shows
An Indiana-based pharmaceutical company and major player in the GLP-1 weight loss drug market, competing with Novo Nordisk through products like Zepbound and Mounjaro while also developing next-generation therapies including retitrutide and Alzheimer's treatments. The company has gained significant podcast attention due to strong financial performance, market share gains, involvement in Trump administration drug pricing initiatives, and strategic innovations like Lilly Direct for direct-to-patient medication delivery. Discussions also cover competitive pressures from compounded alternatives, patent cliff exposure, and pricing dynamics within the pharmaceutical supply chain.
Mentioned On
Episode Mentions
Armstrong & Getty On Demand · Apr 2, 2026
Oh My God I Hate The Left
“Manufacturer of Mounjaro, newly FDA-approved GLP-1 weight-loss drug with daily pill formulation”
NPR News Now · Apr 2, 2026
NPR News: 04-01-2026 8PM EDT
“FDA approved its new obesity pill Fendayo with novel ingredient orforglipron, positioning as alternative to injectable GLP-1 drugs”
PBS News Hour - Full Show · Apr 1, 2026
April 1, 2026 - PBS News Hour full episode
“FDA approved new weight loss pill Foundayo; expected to ship Monday at $25-349/month depending on insurance coverage”
Mad Money w/ Jim Cramer · Apr 1, 2026
Mad Money w/ Jim Cramer 4/1/26
“Pharmaceutical company approved Foundail GLP-1 weight loss pill and acquired Centessa Pharmaceuticals for neurological disorder research”
CNBC's "Fast Money" · Apr 1, 2026
Markets Rally Ahead of Trump’s Iran Address… And Fading The Bounce 4/1/26
“FDA approved Mounjaro oral obesity pill (Fondayo) with 12% weight loss efficacy, launching 3 months after Novo Nordisk's oral Wegovy”
CNBC's "Fast Money" · Mar 31, 2026
Stocks Rally On Optimism For End Of Iran War… And Apple’s Mag-7 Outperformance 3/31/26
“Announced $7.8 billion acquisition of Cintessa for sleep disorder drug pipeline; CEO Dave Ricks highlighted potential for new Rexin agonist class”
Motley Fool Money · Mar 31, 2026
Nobody Told Us This Was M&A Week
“Pharmaceutical company acquiring clinical-stage biotech Centessa for $7.8 billion to diversify beyond GLP-1s”
Peak Performance Life Podcast · Mar 31, 2026
EPI 245: What They Don't Tell You About ANTIDEPRESSANT Drugs. With Psychiatrist Dr. Joanna Moncrieff
“Pharmaceutical company that partially funded the 'Defeat Depression Campaign' in the UK and marketed Prozac (first SSRI) alongside the chemical imbalance narrative”
TBPN · Mar 23, 2026
The Great Peptide Debate with Martin Shkreli & Max Marchione
“Pharmaceutical company developing retatrutide and other peptide-based drugs like GLP-1 agonists”
Lex Fridman Podcast · Mar 23, 2026
#494 – Jensen Huang: NVIDIA – The $4 Trillion Company & the AI Revolution
“Pharmaceutical company; discussed as beneficiary of NVIDIA's open-source biology AI models for drug discovery.”
TBPN · Mar 19, 2026
FULL INTERVIEW: Mark Cuban on Robots, AI, Self-Driving, and Advice to Students
“Pharmaceutical company working on direct-to-patient GLP-1 drug distribution”
TBPN · Mar 18, 2026
Nvidia Restarts China Sales, Vibe Coding Backlash, Peptide Craze | Diet TBPN
“Pharmaceutical company developing retatrutide peptide drug mentioned in health optimization debate”
Decoded | Unlock The Secrets of Human Behavior, Emotion and Motivation · Mar 13, 2026
Peptides Explained: The Truth About Biohacking, Healing & Human Potential with Chris Duffin
“Conducted Phase 3 trials on Retatrutide (triple agonist GLP), showing 68.8 lbs average weight loss and 80% pain reduction in arthritis patients”
Bannon`s War Room · Mar 9, 2026
Episode 5201: The Lies Of John Cornyn
“Sued by Ken Paxton as Texas AG for insulin pricing practices”
The a16z Show · Mar 9, 2026
Andrew Huberman: Peptides, Sleep Tech, and the End of Obesity
“Developing retatrutide (GLP-3) drug and working to prevent compounding pharmacy competition”
Moonshots with Peter Diamandis · Mar 5, 2026
Financializing Super Intelligence, Amazon's $50B Late Fee | #235
“Approaching trillion-dollar market cap with GLP-1 drugs as first anti-aging pharmaceuticals”
Pablo Torre Finds Out · Mar 5, 2026
Share & Bubble & Tell with Mina Kimes and Derek Thompson
“CEO stated large language models are 'basically worthless' for drug discovery applications”
Danny Jones Podcast · Feb 27, 2026
#374 - Ex-Pharma Insider Exposes the $368 Billion Health Insurance Scam | Brigham Buhler
“Launched Cialis and OxyContin; sued compounding pharmacies for making GLP-1 drugs despite FDA request”
Marketplace All-in-One · Feb 26, 2026
What it costs to become an Olympian or Paralympian
“Indiana-based pharma company competing in GLP-1 market, participating in Trump administration price agreements”
Marketplace Morning Report · Feb 26, 2026
What it costs to become an Olympian or Paralympian
“Indiana-based pharma manufacturer participating in Trump administration pricing agreements; stock down 3% amid GLP-1 competition”
Mind Pump: Raw Fitness Truth · Feb 26, 2026
2802: The State of the Hormone & Peptide Industry w/ Vita Bella Founder Phil Vella
“Pharmaceutical company sued by Strive Pharmacy for attempting to suppress compounding of GLP-1s like tirzepatide”
Mad Money w/ Jim Cramer · Feb 25, 2026
Mad Money w/ Jim Cramer 2/24/26
“Parent company of Elanco; mentioned as superior drug maker vs. Novo Nordisk in GLP-1 market”
Morning Wire · Feb 24, 2026
Evening Wire: Cartel Pressure Continues & Mamdani’s Shovel Struggles | 2.24.26
“Competing with Novo Nordisk for GLP-1 drug market share and Trump administration deals”
Morning Brew Daily · Feb 24, 2026
Fictional Story Tanks Stock Market & The iPod Making a Comeback?
“Pharmaceutical company outperforming Novo Nordisk in GLP-1 obesity drug trials; Zepbound showed better weight loss than Novo's Cagrasemma”
CNBC's "Fast Money" · Feb 23, 2026
Tariffs, Banks & Private Credit Jitters… And Crypto Below $65K 2/23/26
“GLP-1 weight loss drug leader gaining market share from Novo Nordisk, trading at reasonable 31x forward earnings with 40% growth”
Moonshots with Peter Diamandis · Feb 19, 2026
Ben Horowitz: xAI Executive Exodus, Apple's AI Crisis, The Pace of AI | #232
“Partner with A16Z on Lilly Direct for AI-generated medical prescriptions”
My First Million · Feb 16, 2026
Asking Scott Galloway 10 Questions We’re Not Allowed To Ask (unfiltered)
“GLP-1 drug manufacturer; Galloway proposed government RFP for billion doses to distribute free to rural households”
Relentless · Feb 14, 2026
The Quest to Cure Alzheimer's | Sacha Schermerhorn, Babylon Bio
“Developing Donanemab (Kasunla) and tau-targeting therapies for Alzheimer's treatment”
The Jesse Kelly Show · Feb 11, 2026
GOP Takes HUGE Step Toward Accountability in Jack Smith Arctic Frost Probe
“Pharmaceutical company funding the American Academy of Pediatrics vaccine schedule decisions”
Well with Arielle Lorre · Feb 11, 2026
439: Botched Beauty: When Anti-Aging Goes Too Far & What to Do Instead with Dr. Terry Dubrow
“Developing retitrutide with myostatin inhibitor for weight loss and muscle gain; Phase 2 trials showing game-changing results expected within 2 years”
CNBC's "Fast Money" · Feb 6, 2026
Mini Correction or Fundamental Rethinking?… And Bitcoin Bounces Back After Plunge 2/6/26
“GLP-1 competitor with over 30% patent cliff exposure; facing competitive pressure from compounded alternatives.”
Prof G Markets · Feb 5, 2026
Google Doubles Down on Spending as AI Fear Returns
“GLP-1 market leader; Q4 revenue up 43% YoY; raised 2026 guidance to $80B with 25% projected sales growth; stock up 10% post-earnings”
Mad Money w/ Jim Cramer · Feb 5, 2026
Mad Money w/ Jim Cramer 2/4/26
“GLP-1 competitor gaining market share with superior efficacy (21% vs 15% weight loss) and maintaining pricing power despite competition”
CNBC's "Fast Money" · Feb 4, 2026
Alphabet Reports Results… And Pharma Stocks Diverge In Weight Loss Drug Race 2/4/26
“Weight loss drug maker surged 10%+ on strong earnings; Zepbound/Mounjaro driving 27% sales growth guidance for 2026”
The Megyn Kelly Show · Jan 30, 2026
Trump's 2026 Cabinet Kickoff, Man Rams Car Into Jewish Center, Social Media on Trial: AM Update 1/30
“Signed MFN pharmaceutical pricing agreement with Trump administration; building six new plants including API manufacturing facility”
The Matt Walsh Show · Jan 28, 2026
Ep. 1724 - The Somali Fraud In Minnesota Is Just The Tip Of The Iceberg. This State Is Even WORSE.
“Pharmaceutical company ran body positivity ad during football games promoting weight loss drug”
Global Security Briefing · Jan 28, 2026
Greenland: A Flashpoint in Transatlantic Relations
“Second-largest insulin producer globally, part of concentrated pharmaceutical supply chain discussion”
Habits and Hustle · Jan 27, 2026
Episode 523: Ashley Koff, RD: GLP-1, Weight Loss and the Mistakes That Create Rebound
“Manufacturer of tirzepatide (Mounjaro, Zepbound); discussed as dual-agonist alternative with faster weight loss but more side effects”
The Al Franken Podcast · Jan 25, 2026
Wendell Potter on The Healthcare Crisis
“Pharmaceutical company subject to PBM rebate demands; example of drug maker forced to pay kickbacks to PBMs for formulary placement”
All-In with Chamath, Jason, Sacks & Friedberg · Jan 24, 2026
Healthcare Needs Builders, Not Bureaucrats: Dr. Mehmet Oz Live from Davos
American History Tellers · Jan 21, 2026
Conquering Polio | The Cutter Fiasco | 3
“Pharmaceutical manufacturer contracted to produce Salk vaccine for 1954 field trials; some batches failed safety testing”
We're Out of Time · Jan 20, 2026
The Future of Addiction Treatment Starts Here: GLP-1s Explained With Dr. Ken Spielvogel
“Manufacturer of Zepbound (terzepatide); Lilly Direct program offers direct-to-patient medication delivery at reduced cost”
My First Million · Jan 19, 2026
Story Of The Most Important Founder You've Never Heard Of
TBPN · Jan 13, 2026
We're all Jerome Powell, Apple and Google Make it Official, Anthropic Health Care | Diet TBPN
Something You Should Know · Jan 5, 2026
How Ozempic and Similar Weight Loss Drugs Really Work & The Story of Money
“Pharmaceutical manufacturer producing Munjaro and Zepbound as competing GLP-1 weight loss and diabetes medications”
Ologies with Alie Ward · Dec 24, 2025
Attention-Deficit Neuropsychology (ADHD) Part 1 Encore with Russell Barkley
“Pharmaceutical company that developed Strattera, a non-stimulant norepinephrine reuptake inhibitor for ADHD treatment”
Short Wave · Dec 19, 2025
GLP-1 Pills Are On The Way. Here's What To Know
“Manufactures Mounjaro and Zepbound injectables; developing Orforglipron, a novel non-peptide GLP-1 pill with later approval timeline”
unPAUSED with Dr. Mary Claire Haver · Nov 18, 2025
GLP-1s and Midlife Metabolism Part 2: Dr. Rocio Salas Whalen Breaks Down the Science of Weight Loss and Menopause
“Manufacturer of tirzepatide (Mounjaro, Zepbound); discussed pricing, vial availability, and lawsuits against compounding pharmacies”
unPAUSED with Dr. Mary Claire Haver · Nov 11, 2025
GLP-1s and Midlife Metabolism: Dr. Rocio Salas-Whalen Breaks Down the Science of Weight Loss and Menopause: Part 1
“Manufacturer of tirzepatide (Monjaro, Zepbound), GLP-1 medication highlighted for lower nausea profile”
All-In with Chamath, Jason, Sacks & Friedberg · Nov 7, 2025
Does OpenAI Need a Bailout? Mamdani Wins, Socialism Rising, Filibuster Nuclear Option
“Announced $149 GLP-1 pricing as part of Trump administration's affordability initiatives”